rs1840680 single nucleotide polymorphism in Pentraxin 3: a potential protective biomarker of severe community-acquired pneumonia

Abstract

Objective Single nucleotide polymorphisms (SNPs) of pentraxin 3 ( PTX3) are associated with various outcomes of lung infections. This study aimed to analyze the relationship between PTX3 polymorphisms and the severity of community-acquired pneumonia (CAP). Methods This is a retrospective case-control study comprising 43 patients with severe CAP (SCAP) and 97 patients with non-severe CAP. Three SNPs in the PTX3 gene (rs2305619, rs3816527, and rs1840680) from peripheral blood samples were genotyped by real-time polymerase chain reaction. The association between each SNP and the CAP severity was analyzed by logistic regression analysis. Results We found that the rs1840680 polymorphism was significantly associated with CAP clinical severity. However, no such association was observed for the genotypes and allele frequencies of rs2305619 or rs3816527. The PTX3 rs1840680 AG genotype was an independent factor for a lower risk of SCAP after multivariate logistic regression analysis. Male sex and coronary heart disease were associated with an increased risk of SCAP. Conclusions The PTX3 rs1840680 AG genotype was found to be associated with a lower risk of SCAP, and may serve as a potential protective biomarker to help clinical judgment and management.

Diagnostic and Prognostic Value of Dysregulated miR-10a-3p in Patients with Severe Pneumonia

“…With the further deterioration of the disease, patients may be accompanied by septic shock, respiratory failure, etc., and even further develop into acute respiratory distress syndrome, encephalopathy or multiple organ dysfunction, which not only increases the burden of medical and health systems, but also brings huge socio-economic losses. 2 Therefore, the early identification and evaluation of the severity of pneumonia patients is of great significance for the rational allocation of medical resources, the formulation of appropriate treatment plans, the prevention of disease deterioration and the improvement of patients’ prognosis. At present, many non-specific indicators may be related to the severity of severe pneumonia, such as C-reactive protein (CRP) and procalcitonin (PCT), but the specificity of these indicators is not enough to accurately reflect severe pneumonia.…”